Article
Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Cancer research - 1 Feb 2002
Szepeshazi Karoly, Schally Andrew V, Halmos Gabor, Armatis Patricia, Hebert Francine, Sun Baodong, Feil Anita, Kiaris Hippokratis, Nagy Attila
Abstract excerpt
The resistance of advanced colorectal cancers to therapy is often related to mutations in the p53 tumor suppressor gene. Because somatostatin (SRIF) receptors (ssts) are present in colorectal carcinomas, the treatment with targeted cytotoxic SRIF analogue AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201) linked to octapeptide SRIF carrier RC-121, may overcome this resistance by producing a higher...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.